Results 61 to 70 of about 2,566,443 (193)

Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases

Clinical Medicine Insights: Cardiology
The association between hyperuricemia and cardiovascular diseases has been studied for many years. Research has shown a link between high uric acid levels and increased risk of including coronary artery disease hypertension and other cardiovascular ...
Franklin Sosa, Mohammed Shaban, Jose Lopez, Gustavo J. Duarte, Swati Jain, Asma Khizar, Timothy Vittorio, Rishabh Mishra, Miguel Rodriguez Guerra   +8 more
doaj   +1 more source

The GPX3‐VCAM1 Axis Gates Pro‐Fibrotic Tubule Cell Fate in Hyperuricemic Nephropathy

Advanced Science, EarlyView.
Hyperuricemia induces NLRP3 inflammasome signaling activation and downregulation of GPX3 in proximal tubular epithelial cells, leading to oxidative stress–driven VCAM1 upregulation, emergence of pro‐fibrotic proximal tubule cells, macrophage recruitment, and renal fibrosis.
Yunfei Qi, Qiang Zhao, Yue Lve, Yaming Yuan, Tingting Zhou, Yue Yuan, Dexi Wu, Yifan Tang, Yan Liu, Zhigang Li, Chunping Jiang, Qiurong Ding   +11 more
wiley   +1 more source

Problems of adherence to therapy in patients with gout in real clinical practice

Consilium Medicum
Aim. To evaluate treatment adherence among patients with gout. Materials and methods. One hundred and thirty-eight patients with gout were examined in the Dzhanelidze Saint Petersburg Research Institute of Emergency Care; 89.9% of them are men and 10 ...
Elena V. Shchemeleva, Elena A. Skorodumova   +1 more
doaj   +1 more source

A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations

Терапевтический архив, 2017
The review analyzes in detail the management of gout, which takes into account its onset and course and the presence of comorbidity. Emphasis is placed on drug and non-drug treatments and urate-lowering therapy in patients with kidney dysfunction.
V V Tsurko, M A Gromova
doaj   +1 more source

Principles of urate-lowering therapy: eight steps to success

Современная ревматология, 2023
Treatment of such a serious systemic disease as gout is often carried out incorrectly, despite the presence of a large number of recommendations and drugs.
O. V. Zhelyabina, M. S. Eliseev, A. M. Lila   +2 more
doaj   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial [PDF]

The American Journal of Medicine, 2019
The purpose of this study was to test a pharmacist-led intervention to improve gout treatment adherence and outcomes.We conducted a site-randomized trial (n=1463 patients) comparing a 1-year, pharmacist-led intervention to usual care in patients with gout initiating allopurinol.
Ted R. Mikuls, T. Craig Cheetham, Gerald D. Levy, Nazia Rashid, Artak Kerimian, Kimberly J. Low, Brian W. Coburn, David T. Redden, Kenneth G. Saag, P. Jeffrey Foster, Lang Chen, Jeffrey R. Curtis   +11 more
openaire   +2 more sources

Urate-lowering therapy (ULT).

, 2015
1Answers in agreement with the 2012 American College of Rheumatology gout guidelines2participants who reported not to adjust ULT for patients with tophaceous gout based on the SUA level were excluded from other questions that were based on the concept of
Geraldo da Rocha Castelar-Pinheiro (783431), H. Ralph Schumacher Jr. (443559), Ana Beatriz Vargas-Santos (783430), Evandro Silva Freire Coutinho (107557), Naomi Schlesinger (783432), Jasvinder A. Singh (484385)   +5 more
core   +1 more source

Update on the Clinical Management of Gout: A Focused Review for the Primary Care Physician

International Journal of Clinical Practice
Gout confers significant burden to patients and is often undertreated despite the availability of safe and efficacious therapies. Undertreatment likely stems from clinical providers’ concerns navigating the complexities of initiating and escalating urate-
Riya Madan, Ted R. Mikuls, Joshua F. Baker, Brian W. Coburn   +3 more
doaj   +1 more source